These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 12410503)

  • 1. Resolution of refractory no-reflow with intracoronary epinephrine.
    Skelding KA; Goldstein JA; Mehta L; Pica MC; O'Neill WW
    Catheter Cardiovasc Interv; 2002 Nov; 57(3):305-9. PubMed ID: 12410503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intracoronary epinephrine in the treatment of refractory no-reflow after primary percutaneous coronary intervention: a retrospective study.
    Aksu T; Guler TE; Colak A; Baysal E; Durukan M; Sen T; Guray U
    BMC Cardiovasc Disord; 2015 Feb; 15():10. PubMed ID: 25885120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of intracoronary administration of anisodamine on slow reflow phenomenon following primary percutaneous coronary intervention in patients with acute myocardial infarction.
    Fu XH; Fan WZ; Gu XS; Wei YY; Jiang YF; Wu WL; Li SQ; Hao GZ; Wei QM; Xue L
    Chin Med J (Engl); 2007 Jul; 120(14):1226-31. PubMed ID: 17697572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intracoronary boluses of adenosine and sodium nitroprusside in combination reverses slow/no-reflow during angioplasty: a clinical scenario of ischemic preconditioning.
    Parikh KH; Chag MC; Shah KJ; Shah UG; Baxi HA; Chandarana AH; Naik AM; Shah JN; Shah HD; Goyal RK
    Can J Physiol Pharmacol; 2007; 85(3-4):476-82. PubMed ID: 17612657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epinephrine: a new pharmacologic treatment for no-reflow?
    Baim DS
    Catheter Cardiovasc Interv; 2002 Nov; 57(3):310-1. PubMed ID: 12410504
    [No Abstract]   [Full Text] [Related]  

  • 6. Coronary hemodynamics before and after rotational atherectomy with adjunctive balloon angioplasty.
    Núñez BD; Keelan ET; Higano ST; Lerman A; Garratt KN; Holmes DR
    Cathet Cardiovasc Diagn; 1996; Suppl 3():40-9. PubMed ID: 8874927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of no-reflow and impaired flow with the nitric oxide donor nitroprusside following percutaneous coronary interventions: initial human clinical experience.
    Hillegass WB; Dean NA; Liao L; Rhinehart RG; Myers PR
    J Am Coll Cardiol; 2001 Apr; 37(5):1335-43. PubMed ID: 11300444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of combination therapy of adenosine and nitroprusside with adenosine alone in the treatment of angiographic no-reflow phenomenon.
    Barcin C; Denktas AE; Lennon RJ; Hammes L; Higano ST; Holmes DR; Garratt KN; Lerman A
    Catheter Cardiovasc Interv; 2004 Apr; 61(4):484-91. PubMed ID: 15065143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. REstoration of COronary flow in patients with no-reflow after primary coronary interVEntion of acute myocaRdial infarction (RECOVER).
    Huang D; Qian J; Ge L; Jin X; Jin H; Ma J; Liu Z; Zhang F; Dong L; Wang X; Yao K; Ge J
    Am Heart J; 2012 Sep; 164(3):394-401. PubMed ID: 22980307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction of major adverse cardiac events with intracoronary compared with intravenous bolus application of abciximab in patients with acute myocardial infarction or unstable angina undergoing coronary angioplasty.
    Wöhrle J; Grebe OC; Nusser T; Al-Khayer E; Schaible S; Kochs M; Hombach V; Höher M
    Circulation; 2003 Apr; 107(14):1840-3. PubMed ID: 12682003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intracoronary versus intravenous administration of abciximab in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with thrombus aspiration: the comparison of intracoronary versus intravenous abciximab administration during emergency reperfusion of ST-segment elevation myocardial infarction (CICERO) trial.
    Gu YL; Kampinga MA; Wieringa WG; Fokkema ML; Nijsten MW; Hillege HL; van den Heuvel AF; Tan ES; Pundziute G; van der Werf R; Hoseyni Guyomi S; van der Horst IC; Zijlstra F; de Smet BJ
    Circulation; 2010 Dec; 122(25):2709-17. PubMed ID: 21098442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increase of myocardial salvage and left ventricular function recovery with intracoronary abciximab downstream of the coronary occlusion in patients with acute myocardial infarction treated with primary coronary intervention.
    Bellandi F; Maioli M; Gallopin M; Toso A; Dabizzi RP
    Catheter Cardiovasc Interv; 2004 Jun; 62(2):186-92. PubMed ID: 15170708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of intracoronary nicardipine in the treatment of no-reflow during percutaneous coronary intervention.
    Huang RI; Patel P; Walinsky P; Fischman DL; Ogilby JD; Awar M; Frankil C; Savage MP
    Catheter Cardiovasc Interv; 2006 Nov; 68(5):671-6. PubMed ID: 17034064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intracoronary administration of abciximab acutely increases flow through culprit vessels of patients with acute coronary syndromes undergoing percutaneous coronary intervention.
    Burzotta F; Romagnoli E; Trani C; Crea F
    Circulation; 2003 Nov; 108(19):e138; author reply e138. PubMed ID: 14610001
    [No Abstract]   [Full Text] [Related]  

  • 15. [Effects of intracoronary administration of nitroglycerin and verapamil for treatment of coronary slow flow phenomenon].
    Chang SF; Ma JY; Qian JY; Shu XH; Ge JB
    Zhonghua Xin Xue Guan Bing Za Zhi; 2010 Jan; 38(1):27-30. PubMed ID: 20398484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical experience with a novel intracoronary perfusion catheter to treat no-reflow phenomenon in acute coronary syndromes.
    Maluenda G; Ben-Dor I; Delhaye C; Gonzalez MA; Collins SD; Torguson R; Xue Z; Suddath WO; Satler LF; Kent KM; Lindsay J; Pichard AD; Waksman R
    J Interv Cardiol; 2010 Apr; 23(2):109-13. PubMed ID: 20337859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intracoronary verapamil for reversal of no-reflow during coronary angioplasty for acute myocardial infarction.
    Werner GS; Lang K; Kuehnert H; Figulla HR
    Catheter Cardiovasc Interv; 2002 Dec; 57(4):444-51. PubMed ID: 12455077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of no-reflow in degenerated saphenous vein graft interventions: comparison of intracoronary verapamil and nitroglycerin.
    Kaplan BM; Benzuly KH; Kinn JW; Bowers TR; Tilli FV; Grines CL; O'Neill WW; Safian RD
    Cathet Cardiovasc Diagn; 1996 Oct; 39(2):113-8. PubMed ID: 8922307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intracoronary administration of abciximab during percutaneous coronary interventions: should this be the routine and preferred approach?
    Sharma S; Makkar R; Lardizabal J
    J Cardiovasc Pharmacol Ther; 2006 Jun; 11(2):136-41. PubMed ID: 16891291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of no flow/slow reflow phenomenon in primary PCI by Nicorandil.
    J E; Juneja MS; George T; Sr R; V V; Ak B; Kalyani S; Pandurangi UM; Latchumanadhas K; S MA
    Indian Heart J; 2007; 59(3):246-9. PubMed ID: 19124934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.